Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2011

Merck BioVentures Taps Parexel to Help Develop a Range of Biosimilars

  • Merck is relying on the expertise of pharmaceutical services provider Parexel to help its Merck BioVentures division develop new biosimilars. Under terms of the deal a dedicated Merck BioVentures unit will be set up within the Parexel organization.

    The strategic alliance will see Parexel provide its new partner with access to a range of regulatory strategy and clinical development planning capabilities for specific classes of biosimilars spanning a number of therapeutic areas, including exclusivity for certain candidates.

    “This agreement positions Merck BioVentures for success with an industry leading partner that has the expertise and resources to conduct clinical development of our diverse portfolio of candidates to allow timely delivery of products to the marketplace,” remarks Michael Kamarck, president of Merck BioVentures.

    Merck announced the establishment of its Merck BioVentures business at the end of 2008, to exploit its glyco-engineering technology for the development of follow-on biologics. Parexel is a global bio/pharmaceutical services organization with operations spanning 54 countries. The firm offers a broad range of clinical development capabilities, integrated advanced technologies, regulatory affairs consulting, and commercialization services.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »